MX2020009743A - Anticuerpos monoclonales neutralizantes de alta afinidad dirigidos contra el ligando de muerte programada 1 (pd-l1) y usos de estos. - Google Patents

Anticuerpos monoclonales neutralizantes de alta afinidad dirigidos contra el ligando de muerte programada 1 (pd-l1) y usos de estos.

Info

Publication number
MX2020009743A
MX2020009743A MX2020009743A MX2020009743A MX2020009743A MX 2020009743 A MX2020009743 A MX 2020009743A MX 2020009743 A MX2020009743 A MX 2020009743A MX 2020009743 A MX2020009743 A MX 2020009743A MX 2020009743 A MX2020009743 A MX 2020009743A
Authority
MX
Mexico
Prior art keywords
monoclonal antibodies
high affinity
programmed death
neutralizing monoclonal
death ligand
Prior art date
Application number
MX2020009743A
Other languages
English (en)
Inventor
Thomas Vincent
Richard Shimkets
Crystal Jackson
Original Assignee
Abeome Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abeome Corp filed Critical Abeome Corp
Publication of MX2020009743A publication Critical patent/MX2020009743A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se divulgan en la presente moléculas de fijación a PD-L1 novedosas y métodos para su uso. Las moléculas de fijación a PD-L1 divulgadas incluyen anticuerpos anti-PD-L1 neutralizantes, anticuerpos biespecíficos e inmunotoxinas. La descripción proporciona el uso de las 5 moléculas de fijación a PD-L1 divulgadas en el tratamiento, la prevención, la inhibición o la reducción de un tipo de cáncer o metástasis o como parte de un régimen de tratamiento que incluye el uso de otros agentes antineoplásicos.
MX2020009743A 2018-03-19 2019-03-19 Anticuerpos monoclonales neutralizantes de alta afinidad dirigidos contra el ligando de muerte programada 1 (pd-l1) y usos de estos. MX2020009743A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862644832P 2018-03-19 2018-03-19
PCT/US2019/022971 WO2019183093A1 (en) 2018-03-19 2019-03-19 High affinity neutralizing monoclonal antibodies to programmed death ligand 1 (pd-l1) and uses thereof

Publications (1)

Publication Number Publication Date
MX2020009743A true MX2020009743A (es) 2020-10-08

Family

ID=67987535

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020009743A MX2020009743A (es) 2018-03-19 2019-03-19 Anticuerpos monoclonales neutralizantes de alta afinidad dirigidos contra el ligando de muerte programada 1 (pd-l1) y usos de estos.

Country Status (10)

Country Link
US (1) US20210017284A1 (es)
EP (1) EP3768719A4 (es)
JP (2) JP2021518380A (es)
KR (1) KR20210003099A (es)
CN (1) CN111954682A (es)
AU (1) AU2019239850A1 (es)
CA (1) CA3094534A1 (es)
IL (1) IL277429A (es)
MX (1) MX2020009743A (es)
WO (1) WO2019183093A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110612117B (zh) 2018-04-17 2024-04-12 分子模板公司 包含去免疫化的志贺毒素a亚基支架的her2靶向分子
WO2021055816A1 (en) 2019-09-18 2021-03-25 Molecular Templates, Inc. Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds
MX2022003195A (es) 2019-09-18 2022-04-11 Molecular Templates Inc Moleculas de union a pd-l1 que comprenden andamios de la subunidad a de la toxina shiga.
EP4262858A1 (en) 2020-12-16 2023-10-25 Molecular Templates, Inc. Clinical methods for use of a pd-l1-binding molecule comprising a shiga toxin effector
WO2022197945A1 (en) 2021-03-17 2022-09-22 Molecular Templates, Inc. Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6979564B2 (en) * 2000-10-20 2005-12-27 Millennium Pharmaceuticals, Inc. 80090, human fucosyltransferase nucleic acid molecules and uses thereof
ATE525398T1 (de) * 2002-05-10 2011-10-15 Medimmune Inc Epha2 monoklonale antikörper und deren anwendungsverfahren
DK2439273T3 (da) * 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
PT1907424E (pt) * 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
KR20090114430A (ko) * 2007-02-02 2009-11-03 베일러 리서치 인스티튜트 항원-제시 세포 상에서 발현된 ｄｃｉｒ에 대한 항원 표적화에 기초한 백신
EP2130552B1 (en) * 2007-02-27 2016-06-15 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising anti-grp78 antibody as active ingredient
MA33208B1 (fr) * 2009-03-25 2012-04-02 Genentech Inc Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
KR101764096B1 (ko) * 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
TWI680138B (zh) * 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
PE20170255A1 (es) * 2014-01-24 2017-03-22 Dana Farber Cancer Inst Inc Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
KR102476226B1 (ko) * 2014-08-05 2022-12-12 아폴로믹스 인코포레이티드 항-pd-l1 항체
US9535074B2 (en) * 2014-09-08 2017-01-03 Merck Sharp & Dohme Corp. Immunoassay for soluble PD-L1
EP3227340B1 (en) * 2014-12-04 2020-06-17 Mediterranea Theranostic S.R.L. Humanized anti-trop-2 monoclonal antibodies and uses thereof
US10537633B2 (en) * 2016-03-04 2020-01-21 Jn Biosciences Llc Antibodies to TIGIT
US10669338B2 (en) * 2016-06-17 2020-06-02 Immunomedics, Inc. Anti-PD-1 checkpoint inhibitor antibodies that block binding of PD-L1 to PD-1

Also Published As

Publication number Publication date
CN111954682A (zh) 2020-11-17
JP2024009883A (ja) 2024-01-23
CA3094534A1 (en) 2019-09-26
EP3768719A4 (en) 2022-04-27
AU2019239850A1 (en) 2020-10-29
JP2021518380A (ja) 2021-08-02
US20210017284A1 (en) 2021-01-21
IL277429A (en) 2020-11-30
EP3768719A1 (en) 2021-01-27
WO2019183093A1 (en) 2019-09-26
WO2019183093A8 (en) 2020-06-11
KR20210003099A (ko) 2021-01-11

Similar Documents

Publication Publication Date Title
MX2020009743A (es) Anticuerpos monoclonales neutralizantes de alta afinidad dirigidos contra el ligando de muerte programada 1 (pd-l1) y usos de estos.
NZ738979A (en) Pd-1 antibodies
PH12019500270A1 (en) Combination therapy for cancer
ZA202006859B (en) Antibodies specific for gucy2c and uses thereof
MX2019009967A (es) Moleculas de union biespecificas que son capaces de unirse a cd137 y a antigenos tumorales, y usos de las mismas.
MX2021003685A (es) Inhibicion dirigida del factor de crecimiento transformador b (tgfb).
TN2019000272A1 (en) Anti-ilt4 antibodies and antigen-binding fragments.
MX2021015888A (es) Fusión de un anticuerpo que se une a cea y 4-1bbl.
MX2023005375A (es) Anticuerpos trivalentes biespecificos unidos a claudina 6 o claudina 18.2 y cd3 para el tratamiento de enfermedades de cancer que expresan claudina.
MY179866A (en) Bi-specific monovalent diabodies that are capable of binding to gpa33 and cd3, and uses thereof
TN2016000046A1 (en) Bi-specific monovalent diabodies that are capable of binding cd123 and cd3, and uses therof
EA201891428A1 (ru) Комбинация антител к pd-1 и биспецифических антител к cd20/cd3 для лечения злокачественной опухоли
NZ739028A (en) Humanized or chimeric cd3 antibodies
MX393609B (es) Anticuerpos anti pd-1 y anti-lag3 para el tratamiento de cancer
MA40074A (fr) Composés liant ras multivalents
PH12021553145A1 (en) Multispecific heavy chain antibodies binding to cd22 and cd3
PH12018550179A1 (en) Anti-pd-1 antibodies, method for producing same and method for using same
CA2886433C (en) Human monoclonal anti-pd-l1 antibodies and methods of use
MY191423A (en) Binding molecules specific for cd73 and uses thereof
MX2021005236A (es) Regimen de dosificacion de anticuerpo anti-tigit para el tratamiento de cancer.
PH12022550056A1 (en) Dll3-targeting antibodies and uses thereof
PH12020551661A1 (en) Anti-pd-l1 antibody and use thereof
EA201990374A1 (ru) Комбинация антитела против cd20, ингибитора pi3-киназы-дельта и антитела против pd-1 или против pd-l1 для лечения гематологических раков
EA202192587A1 (ru) Антитела к cd73, антитела к pd-l1 и химиотерапия для лечения опухолей
MX2021010116A (es) Anticuerpo anti-pd-l1 y uso de este.